Literature DB >> 8420213

Risk factors for motor response complications in L-dopa-treated parkinsonian patients.

A Peppe1, J M Dambrosia, T N Chase.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8420213

Source DB:  PubMed          Journal:  Adv Neurol        ISSN: 0091-3952


× No keyword cloud information.
  6 in total

1.  Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3, 4-dihydroxyphenylalanine administration in Parkinsonian rats.

Authors:  W Y Lee; J W Chang; N L Nemeth; U J Kang
Journal:  J Neurosci       Date:  1999-04-15       Impact factor: 6.167

2.  Chronic anterior pallidal stimulation for Parkinson's disease.

Authors:  R P Iacono; R R Lonser; G Maeda; S Kuniyoshi; D Warner; G Mandybur; S Yamada
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

Review 3.  The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.

Authors:  T N Chase
Journal:  Drugs       Date:  1998       Impact factor: 9.546

4.  A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

Authors:  J L Montastruc; O Rascol; J M Senard; A Rascol
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

5.  Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys.

Authors:  Krystof S Bankiewicz; Marcel Daadi; Philip Pivirotto; John Bringas; Laura Sanftner; Janet Cunningham; John R Forsayeth; Jamie L Eberling
Journal:  Exp Neurol       Date:  2005-12-09       Impact factor: 5.330

6.  Contemporaneous bilateral postero-ventral pallidotomy for early onset "juvenile type" Parkinson's disease. Case report.

Authors:  R P Iacono; R R Lonser; S Yamada
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.